Long-await­ed No­vavax PhI­II re­sults show 90.3% over­all ef­fi­ca­cy, with 100% ef­fec­tive­ness against mod­er­ate and se­vere Covid-19

Af­ter sev­er­al months of de­lays and set­backs, the small Mary­land biotech No­vavax has fi­nal­ly com­plet­ed its North Amer­i­can Phase III tri­al for its Covid-19 vac­cine. And though they say the topline re­sults are pos­i­tive, it re­mains to be seen how much up­take there will be in the US giv­en the wan­ing num­bers of cas­es, ris­ing vac­ci­na­tion rates and a sur­plus of al­ready-au­tho­rized vac­cines.

Over­all ef­fi­ca­cy in the study hit 90.3% across near­ly 30,000 pa­tients in the US and Mex­i­co, No­vavax said, with a to­tal of 77 cas­es ob­served. In the place­bo arm, re­searchers saw 63 cas­es of Covid-19 com­pared to 14 in the vac­cine group. Par­tic­i­pants were ran­dom­ized in­to the vac­cine arm 2 to 1, and No­vavax said it col­lect­ed its da­ta be­tween Jan. 25 and April 30.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER